Lessons from negative phase 3 trials in rheumatoid arthritis anno 2023

Ann Rheum Dis. 2023 Dec;82(12):1503-1505. doi: 10.1136/ard-2023-224904. Epub 2023 Oct 30.

Authors

René Westhovens¹, Patrick Verschueren²

Affiliations

¹ University Hospitals Leuven and KU Leuven Belgium, Leuven, Belgium rene.westhovens@uzleuven.be.
² Rheumatology, KU Leuven University Hospitals, Leuven, Belgium.

PMID: 37903542
DOI: 10.1136/ard-2023-224904

No abstract available

Keywords: Antirheumatic Agents; Arthritis, Rheumatoid; Biological Therapy; Patient Reported Outcome Measures; Therapeutics.

Publication types

Editorial